Technical Analysis for LPCN - Lipocine Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| New Uptrend | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| New Downtrend | Bearish | -6.31% | |
| Crossed Above 20 DMA | Bullish | -6.31% | |
| Wide Bands | Range Expansion | -6.31% | |
| 20 DMA Resistance | Bearish | -0.39% | |
| NR7 | Range Contraction | -0.39% | |
| NR7-2 | Range Contraction | -0.39% | |
| Wide Bands | Range Expansion | -0.39% |
| Alert | Time |
|---|---|
| Down 5% | about 5 hours ago |
| 60 Minute Opening Range Breakdown | about 5 hours ago |
| Down 3% | about 5 hours ago |
| Possible NR7 | about 6 hours ago |
| Rose Above 10 DMA | about 10 hours ago |
Get a Trading Assistant
- Earnings date: 08/08/2024
Lipocine Inc. Description
Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Alcohol Pharmaceutical Products Gastrointestinal Clinical Research Clinical Trial Metabolism Bypass Ketones Testosterone Androstanes Preterm Birth
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.79 |
| 52 Week Low | 2.3101 |
| Average Volume | 53,223 |
| 200-Day Moving Average | 4.22 |
| 50-Day Moving Average | 6.53 |
| 20-Day Moving Average | 8.03 |
| 10-Day Moving Average | 8.36 |
| Average True Range | 1.03 |
| RSI (14) | 50.50 |
| ADX | 32.12 |
| +DI | 25.16 |
| -DI | 22.44 |
| Chandelier Exit (Long, 3 ATRs) | 8.69 |
| Chandelier Exit (Short, 3 ATRs) | 9.37 |
| Upper Bollinger Bands | 9.89 |
| Lower Bollinger Band | 6.18 |
| Percent B (%b) | 0.42 |
| BandWidth | 46.11 |
| MACD Line | 0.43 |
| MACD Signal Line | 0.59 |
| MACD Histogram | -0.1627 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.34 | ||||
| Resistance 3 (R3) | 9.49 | 9.10 | 9.07 | ||
| Resistance 2 (R2) | 9.10 | 8.69 | 9.02 | 8.98 | |
| Resistance 1 (R1) | 8.41 | 8.43 | 8.21 | 8.26 | 8.89 |
| Pivot Point | 8.02 | 8.02 | 7.92 | 7.94 | 8.02 |
| Support 1 (S1) | 7.33 | 7.61 | 7.14 | 7.18 | 6.55 |
| Support 2 (S2) | 6.94 | 7.35 | 6.87 | 6.46 | |
| Support 3 (S3) | 6.25 | 6.94 | 6.37 | ||
| Support 4 (S4) | 6.10 |
